# MANNATECH INC (MTEX) · Edgar & Edgarette company card

> Mannatech (MTEX) saw revenue fall 8.3% in FY2025 to $108 million, operating margin -0.4% against a 0.7% median for medicinal chemicals & botanical products, equity -17.4% of assets, and dividend per share up 1 year running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1056358 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MTEX) · [JSON](https://www.pops4.com/boards/company/MTEX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $108M |
| Revenue growth, 1 year | -8.3% |
| Revenue growth per year | -9.3% |
| Operating margin | -0.4% (prior year 1.2%) |
| Net margin | -14.1% |
| Operating cash flow | −$3M |
| Capital spending | $1M |
| Free cash flow | −$4M |
| Cash | $6M |
| Long-term debt | $3M |
| Total assets | $30M |
| Total equity | −$5M |
| Equity ÷ assets | -17.4% |
| Return on equity | — |
| Dividend per share | $0.2 |
| Dividend years rising | 1 |

## Readings, computed from those figures

- Altman Z: -1.37 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Beneish M: -5.31 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -0.4% in FY2025
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $108.0M (FY2025), total debt $2.8M. Experience: revenue down 8.3% on the year, down 9.3% a year over 4 years; operating margin -0.4%, down from 1.2%. Soundness: equity -17.4% of assets (liabilities exceed assets), dividend per share up 1 year running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $85.5M and $111.0M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $80.0M to $118.9M. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -0.4% against a 0.7% median; growth -8.3% against 1.7%.

Range logged 2026-10-09, receipt c6451d6d914a688e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 2, latest 2026-04-02 ([filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926011099/0001437749-26-011099-index.htm))
- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-04-24 ([filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926013327/0001437749-26-013327-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-10-21 ([filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926033029/0001437749-26-033029-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-09-01 ([filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926029403/0001437749-26-029403-index.htm))

## Recent filings

- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926036551/0001437749-26-036551-index.htm)
- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926036548/0001437749-26-036548-index.htm)
- 8-K · filed 2026-10-21 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926033029/0001437749-26-033029-index.htm)
- 8-K · filed 2026-10-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926032638/0001437749-26-032638-index.htm)
- 8-K · filed 2026-09-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926029403/0001437749-26-029403-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1056358/000143774926027305/0001437749-26-027305-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001056358.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1056358

## Cite

POPS4, Edgar & Edgarette: MANNATECH INC (MTEX) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/MTEX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

